DKN-01: Phase I data

Top-line data from a 2-part, open-label, U.S. Phase I trial in 27 patients with cholangiocarcinoma showed that 150 and 300 mg doses of IV DKN-01 plus gemcitabine and cisplatin on days 1 and 8 of a 21-...